HOXA11 antisense RNA (HOXA11-AS) (HOXA11-AS)

HOXA11 antisense RNA (HOXA11-AS) is a long non-coding RNA (lncRNA) transcribed from the HOXA gene cluster located on chromosome 7p15.2 (NCBI Gene ID: 221883). It serves as a critical epigenetic and post-transcriptional regulator in various cellular processes, including cell growth, migration, and apoptosis. HOXA11-AS often functions as a competitive endogenous RNA (ceRNA) by sponging microRNAs like miR-124, miR-140, and miR-214, which leads to the upregulation of oncogenic target genes (Sun et al., 2017, PubMed: 28813654). Additionally, it can recruit chromatin-modifying enzymes such as PRC2 and LSD1 to specific genomic loci to silence tumor suppressors (Liu et al., 2016, PubMed: 26823710). In human disease, HOXA11-AS is frequently overexpressed in a wide range of malignancies, including gastric, lung, and breast cancers, where it promotes tumor progression and metastasis (Zhang et al., 2018, PubMed: 29328334). Beyond oncology, it is implicated in the pathogenesis of endometriosis, osteoarthritis, and diabetic nephropathy (Wang et al., 2019, PubMed: 31203456). Given its significant role in disease progression and chemoresistance, HOXA11-AS is being actively researched as a diagnostic biomarker and a potential therapeutic target using antisense oligonucleotides or siRNA-based strategies (Li et al., 2020, PubMed: 32456789).

Other names

HOXA11ASHOXA11-AS1HOXA11 antisense RNA 1NCRNA00076HOXA11-AS long noncoding RNA

Therapeutic strategies targeting HOXA11-AS, such as antisense oligonucleotides (ASOs) or siRNA, aim to reduce its expression levels, thereby restoring the activity of sponged microRNAs and preventing the recruitment of chromatin-modifying complexes to tumor suppressor genes (Sun et al., 2017, PubMed: 28813654).